Skip to content
Business

Capricor Sinks 78% After Hours as the FDA Rejects Its Duchenne Therapy a Second Time

The FDA rejected Capricor's Duchenne cell therapy deramiocel for a second time on 20 November, citing serious data integrity problems in the HOPE-3 trial. The shares fell 78% after hours.

Main entrance of FDA Building 1 on the agency's campus in Silver Spring, Maryland, in early morning light
Photo: U.S. Food and Drug Administration / Wikimedia Commons, public domain

Capricor Therapeutics shares were quoted 78% lower in after-hours trading late on Friday 20 November, after the FDA rejected deramiocel, the company's cell therapy for Duchenne muscular dystrophy, for the second time. The agency said "serious clinical trial data integrity deficiencies" in the pivotal HOPE-3 trial make its data unreliable. The San Diego biotech stands by its data and now weighs its next move with about $198.5m of cash and securities.

Capricor after the FDA's letter

  • 78% after-hours fall in the share price, from a $7.59 close to $1.64
  • $198.5m cash, equivalents, restricted cash and marketable securities at 30 September
  • 2 complete response letters for deramiocel, in July 2025 and November 2026

What the FDA said about deramiocel and the HOPE-3 trial

The decision landed two days before the FDA's target date of Sunday 22 November. The agency sent Capricor a complete response letter, the formal notice that an application cannot be approved as it stands, and published a statement explaining why.

An inspection by the FDA's Bioresearch Monitoring programme, which checks how clinical trials are run, found serious deficiencies in HOPE-3. The agency listed three: changes to the statistical analysis plan made after the fact without authorisation, breaches of the blinding rules that keep doctors and families from knowing who received the real treatment, and further protocol violations that, in the FDA's words, "individually and collectively, compromise the reliability of the study data."

No reanalysis can repair that, the FDA said. The problems "amplified" its concerns that HOPE-3 had missed its pre-specified primary and secondary goals, and the agency "cannot approve a product on the basis of data whose reliability has been compromised." Capricor can respond to the inspection findings, which the FDA set out in a separate letter.

On Monday the agency also turned down Summit Therapeutics' lung cancer drug, for want of a clear gain in survival.

Capricor Therapeutics in the three months to 21 November 2026. Daily closing prices from exchange data.
Capricor Therapeutics in the three months to 21 November 2026. Daily closing prices from exchange data.

How Capricor answered the FDA

Capricor does not accept the verdict on its science. "We stand behind the rigor of our clinical program and the integrity of our data, and we believe the data support approval," said chief executive Linda Marbán. She pointed out that both of its double-blind, placebo-controlled trials, HOPE-2 and HOPE-3, met their primary endpoints.

In December 2025 Capricor reported that HOPE-3, which enrolled 106 patients, met its main goal on PUL v2.0, a scale that scores arm and hand function, slowing decline by 54% against placebo with a p-value of 0.029. The FDA's statement did not spell out which changes to the analysis plan it objected to.

One detail stands out. On 10 November, Capricor said the FDA's July inspection had ended with a Form 483, the agency's written list of inspection findings, containing a single observation. Ten days later the FDA called the trial's problems serious enough to make the data unreliable. Three days before that 10 November update, HOPE-3's heart results had won an American Heart Association research award.

DateWhat happened
July 2025First complete response letter for deramiocel
3 December 2025Capricor reports HOPE-3 met its primary endpoint
10 March 2026FDA resumes review; target date set for 22 August
29 July 2026Advisers vote 9 to 3 that the evidence did not show it works for Duchenne heart disease
24 August 2026Review extended to 22 November after a major amendment refocusing the request on upper limb function
20 November 2026Second complete response letter

What the rejection means for Duchenne families

Duchenne is a genetic muscle-wasting disease that mainly affects boys. Damage to the heart muscle leads to heart failure, the most common cause of death. Capricor says about 15,000 people in the US live with it. There is no cure.

Parent Project Muscular Dystrophy, the US patient group, called the decision "devastating" and "heartbreaking news for the Duchenne community", above all for families who gave years to the trials. It said the letter does not, on its own, decide whether trials or access programmes continue, and told families in deramiocel studies to contact their study team. The group said it would seek clarification for participants and work with both Capricor and the FDA, adding that the ruling "does not yet mark the end of the road."

The FDA said it shares families' hope for effective treatments, but that flexibility "cannot come at the cost" of reliable data. On Monday the same agency approved Roche's breast cancer pill Wilserdly.

What happens next for Capricor and its shares

The shares closed Friday's regular session at $7.59, up 0.8%, giving Capricor a market value of about $441m, according to Google Finance data. The company's release went out at 7:55pm New York time, and by 7:59pm the stock was quoted at $1.64 in after-hours trading. Over the past year the shares have traded as high as $40.37 and as low as $2.96.

Capricor says its $198.5m will last at least 12 months, and it is reviewing costs to stretch it. That cushion has been shrinking: it held about $318.1m at the end of 2025, and operating expenses reached $44.7m in the third quarter alone, up from $26.3m a year earlier, mainly on launch preparations and manufacturing. It had already cut about 10% of its staff in that quarter.

Biotech shares can swing just as hard the other way on a single result, as when Kodiak Sciences nearly tripled on phase 3 wins in September. For Capricor, the next clue comes on Monday 23 November, when it hosts a conference call and webcast at 8:30am Eastern time (14:30 in Central Europe).

Why did the FDA reject Capricor's deramiocel?

The FDA rejected deramiocel on 20 November 2026 because it judged the evidence short of the approval standard. It cited serious data integrity problems in the HOPE-3 trial, including unauthorised changes to the statistical analysis plan and breaches of blinding.

Why did Capricor stock fall?

Capricor shares were quoted 78% lower after hours on Friday 20 November, at $1.64 against a $7.59 close, after the FDA rejected deramiocel a second time.

Can patients in deramiocel trials keep getting treatment?

That is not yet clear. Parent Project Muscular Dystrophy said on 21 November that the rejection does not by itself end trials or access programmes, and advised families to ask their study team or treating doctor.

Sources

Related stories

Roche Tower 1 and Roche Tower 2, the company's headquarters buildings in Basel, photographed in March 2021.
Business

Roche Wins FDA Approval for Breast Cancer Pill Wilserdly After 62% Cut in Progression Risk

The FDA approved Roche's all-pill Wilserdly combination for ESR1-mutated advanced breast cancer after it cut the risk of progression or death by 62%. A ruling on early-stage use is…

Novo Nordisk's NN1 headquarters building on Krogshøjvej in Bagsværd, Denmark
Business

Novo Nordisk Says Early CagriSema Responders Lost 25.4% of Body Weight in 68 Weeks

Novo Nordisk says patients who responded early to its obesity shot CagriSema lost 25.4% of their body weight in 68 weeks, but the post hoc analysis is no guide to treatment yet.

The main entrance of FDA Building 1 on the agency's campus in Silver Spring, Maryland, which houses the offices of the commissioner and senior staff.
Investing

FDA Rejects Summit's Lung Cancer Drug Ivonescimab Over Phase 3 Survival Miss

The FDA has rejected Summit Therapeutics' lung cancer drug ivonescimab, saying slower tumour growth in the phase 3 HARMONi trial was not enough without a clear gain in survival.

A skybridge with the Bayer cross and the slogan 'Science For A Better Life' spans Sellerstrasse at Bayer's pharmaceuticals site in Berlin-Wedding.
Business

Bayer Wins FDA Approval for Sunharbo, the First Factor XIa Blood Thinner in the US

Bayer shares rose about 1.5% to their highest since May 2023 after the FDA approved Sunharbo, the first Factor XIa blood thinner in the US, which cut repeat strokes by 26% in its…

PayPal's headquarters building at 2211 North First Street in San Jose, California, photographed in July 2013
Business

PayPal Remakes Its Top Team in One Day and Hires Xero's Claire Bramley as Finance Chief

PayPal has hired Xero finance chief Claire Bramley as CFO from 1 February 2027, succeeding Jamie Miller, and named new heads for Venmo and crypto as its chief risk officer leaves.

Bayer's white pipe bridge reading Science For A Better Life spanning a road in Leverkusen, Germany, April 2015
Business

Bayer's $7.25bn Roundup Settlement Wins Final Approval, Covering Cancers Not Yet Diagnosed

A St. Louis judge gave final approval on 20 November to Bayer's $7.25bn Roundup settlement, paid over up to 21 years, with average awards of $10,000 to $165,000 for cancer…

Line chart of Fireweed Metals daily closing prices in the three months to 21 November 2026
Business

Fireweed Metals Wins Up to C$14m for Mactung, Close to What It Paid for the Whole Deposit

Natural Resources Canada will put up to C$14m into Fireweed Metals' Mactung tungsten project in the Yukon for engineering and test work, but no build cost or start date was given.

Aerial view of Oracle's Riverside campus offices in Austin, Texas, photographed from a drone in March 2018
Business

Oracle Says Its OpenAI Contract Is Fully Funded, Rebutting Reports Before They Even Appear

Oracle says it has all the funding it needs for its OpenAI data-centre contract after a $20bn raise of shares and debt, calling any reports to the contrary wrong. Its shares rose…